Calcitonin
drugOn this page
Also known as CalcitareunspecifiedCalcitoninaCalcitonineCalsynarMiacalcicThrocalcitonin
Summary
Calcitonin (CHEMBL4594242) is an approved protein targeting CALCR; indicated across 3 conditions including postmenopausal osteoporosis and giant cell reparative granuloma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- Targets: 1 (CALCR)
- Indications: 3 conditions
- Clinical trials: 12
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4594242 |
| Name | Calcitonin |
| Type | Protein |
| Max phase | 4 |
Also known as: Calcitare, Calcitonin, unspecified, Calcitonina, Calcitonine, Calsynar, Miacalcic, Throcalcitonin, CALCITONIN
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| CALCR | CT receptor | Full agonist | 11.2 | 0% | P30988 |
| AMY1 receptor | Full agonist | 11.3 | |||
| AMY2 receptor | Full agonist | 11.4 | |||
| AMY3 receptor | Full agonist | 10.6 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): CALCR.
Top Reactome pathways
7 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Signal Transduction | 1 | CALCR |
| Signaling by GPCR | 1 | CALCR |
| Class B/2 (Secretin family receptors) | 1 | CALCR |
| GPCR downstream signalling | 1 | CALCR |
| G alpha (s) signalling events | 1 | CALCR |
| Calcitonin-like ligand receptors | 1 | CALCR |
| GPCR ligand binding | 1 | CALCR |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| ossification | 1 |
| cell surface receptor signaling pathway | 1 |
| adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 |
| positive regulation of cytosolic calcium ion concentration | 1 |
| positive regulation of gene expression | 1 |
| negative regulation of ossification | 1 |
| osteoclast differentiation | 1 |
| regulation of mRNA stability | 1 |
| positive regulation of calcium-mediated signaling | 1 |
| response to glucocorticoid | 1 |
| positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction | 1 |
| positive regulation of ERK1 and ERK2 cascade | 1 |
| calcitonin family receptor signaling pathway | 1 |
| amylin receptor signaling pathway | 1 |
| positive regulation of cAMP/PKA signal transduction | 1 |
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| postmenopausal osteoporosis | 3 | MONDO:0008159 | EFO:0003854 |
| giant cell reparative granuloma | 2 | MONDO:0006770 | EFO:1000950 |
| calcinosis | 2 | MONDO:0002123 | MONDO:0002123 |
Clinical trials
Total trials: 12.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 4 |
| Not specified | 4 |
| PHASE4 | 3 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03935984 | PHASE4 | RECRUITING | Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity |
| NCT00444808 | PHASE4 | TERMINATED | Analgesic Effect of Intranasal Calcitonin on Patients With Fractured Ribs |
| NCT03342001 | PHASE4 | COMPLETED | Hypothyroidism Treated With Calcitonin |
| NCT00486434 | PHASE3 | COMPLETED | Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis |
| NCT00525798 | PHASE3 | COMPLETED | A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D |
| NCT00543218 | PHASE3 | COMPLETED | PTH Comparison in Post Menopausal Women |
| NCT00959764 | PHASE3 | COMPLETED | A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women |
| NCT00004358 | PHASE2 | COMPLETED | Phase II Study of Calcitonin for Tumoral Calcinosis |
| NCT05805683 | Not specified | RECRUITING | Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury |
| NCT00478335 | Not specified | COMPLETED | Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus |
| NCT00688077 | Not specified | COMPLETED | FGF-23 Suppressibility by Calcitonin |
| NCT02115360 | Not specified | COMPLETED | Epidural Calcitonin in Lower Limb Amputation |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
3 molecules share ≥1 primary target. Top 3 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| PRAMLINTIDE | ChEMBL + PubChem | Phase 4 (approved) | CALCR |
| CALCITONIN SALMON | ChEMBL | Phase 4 (approved) | CALCR |
| CAGRILINTIDE | ChEMBL | Phase 3 | CALCR |
Related Atlas pages
- Genes: CALCR
- Diseases: postmenopausal osteoporosis
- Drugs: Pramlintide, Calcitonin Salmon, Cagrilintide